Search
Vincristine
go.drugbank.com/drugs/DB00541ApprovedInvestigationalVincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy … It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar.
Mixtures: MEODEX®, MEODEX®Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexFurazolidone
go.drugbank.com/drugs/DB00614InvestigationalVet approvedA nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone binds bacterial DNA which leads to the gradual inhibition of monoamine oxidase.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Heterocyclic Compounds, 1-RingSynonyms: 5-Nitro-N-(2-oxo-3-oxazolidinyl)-2-furanmethanimine, N-(5-Nitro-2-furfurylidene)-3-amino-2-oxazolidoneMevidalen
go.drugbank.com/drugs/DB19034InvestigationalMevidalen is under investigation in clinical trial NCT03305809 (A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or
Categories: Heterocyclic Compounds, 2-RingSynonyms: 2-(2,6-dichlorophenyl)-1-((1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl)ethanone, Ethanone, 2-(2,6-dichlorophenyl)-1-((1s,3r)-3,4-dihydro-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-2(1h)-isoquinolinyl)-Navocaftor
go.drugbank.com/drugs/DB19039InvestigationalNavocaftor is under investigation in clinical trial NCT04853368 (Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/navocaftor/abbv-119 or Galicaftor/navocaftor
Synonyms: (5-(3-amino-5-((4-(trifluoromethoxy)phenyl)sulfonyl)pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanol, 1,3,4-oxadiazole-2-methanol, 5-(3-amino-5-((4-(trifluoromethoxy)phenyl)sulfonyl)-2-pyridinyl)-Irsenontrine
go.drugbank.com/drugs/DB19044InvestigationalIrsenontrine is under investigation in clinical trial NCT03467152 (Study to Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia
Synonyms: 4h-pyrazolo(4,3-c)quinolin-4-one, 1,5-dihydro-7-(2-methoxy-3,5-dimethyl-4- pyridinyl)-1-((3s)-tetrahydro-3-furanyl)-, 7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-((3s)-tetrahydrofuran-3-yl)-1,5-dihydro-4h-pyrazolo(4,3-c)quinolin-4-oneLartesertib
go.drugbank.com/drugs/DB19045InvestigationalLartesertib is under investigation in clinical trial NCT06433219 (Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (Ddriver EOC 302)).
Synonyms: 2H-Imidazo[4,5-c]quinolin-2-one, 8-(1,3-dimethyl-1H-pyrazol-4-yl)-1-(3-fluoro-5-methoxy-4-pyridinyl)-1,3-dihydro-7-methoxy-3-methyl-, (1S)-, 8-(1,3-dimethyl-1h-pyrazol-4-yl)-1-(3-fluoro-5-methoxy-4-pyridinyl)-1,3-dihydro-7-methoxy-3-methyl-2h-imidazo(4,5-c)quinolin-2-oneBNC-210
go.drugbank.com/drugs/DB19048InvestigationalBNC-210 is under investigation in clinical trial NCT04951076 (A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-traumatic Stress Disorder (PTSD)).
Synonyms: 1,8-NAPHTHYRIDIN-4(1H)-ONE, 6-((2,3-DIHYDRO-1H-INDEN-2-YL)AMINO)-1-ETHYL-3-(4-MORPHOLINYLCARBONYL)-, 6-((2,3-dihydro-1h-inden-2-yl)amino)-1-ethyl-3-(4-morpholinylcarbonyl)-1,8-naphthyridin-4(1h)-oneZandatrigine
go.drugbank.com/drugs/DB19051InvestigationalZandatrigine is under investigation in clinical trial NCT05226780 (Extension Study to Evaluate How Safe and Tolerable NBI-921352 Is as an Adjunctive Therapy for Participants With SCN8A-DEE).
Synonyms: Benzenesulfonamide, 2-fluoro-5-methyl-4-(methyl((3s)-1-(phenylmethyl)-3-pyrrolidinyl)amino)-n-4-thiazolyl-Renvistobart
go.drugbank.com/drugs/DB19065InvestigationalRenvistobart is under investigation in clinical trial NCT02913313 (A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors).
Lerodalcibep
go.drugbank.com/drugs/DB19071ApprovedInvestigationalLerodalcibep is a recombinant fusion protein that binds to and inhibits proprotein convertase subtilisin kexin type 9 (PCSK9). … [L54738] Approved by the FDA on December 15, 2025, lerodalcibep is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia
Categories: Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) InhibitorsSynonyms: Engineered binding protein (1-96) anti-(human proprotein convertase subtilisin/kexin type 9), derived from human tenth fibronectin type iii domain, fused via peptidyl linker (97gsgsgs102) to human serum, Protein lib003 (recombinant human proprotein convertase subtilisin/kexin type 9 ligand-binding tenth fibronectin type iii domain) fusion protein with peptide (synthetic 6-amino acid linker) fusion protein